ROYALTY MONETIZATION$150 million
ADYNOVATE (Antihemophilic Factor (Recombinant), PEGylated) is a recombinant full-length PEGylated human coagulation Factor VIII for the treatment of Hemophilia A. Nektar’s PEGylation technology, originally licensed to Baxter (now Takeda), allows ADYNOVATE to extend its half-life vs. Advate®, with improved dosing. The product was approved in the U.S. in November 2015.
MOVANTIK (naloxegol) is a peripherally acting μ-opioid receptor antagonist that was licensed by Nektar to AstraZeneca where it was developed for the treatment of opioid-induced constipation. MOVANTIK was approved in 2014 in adult patients with chronic, non-cancer pain and is now marketed by RedHill Biopharma.
HCRx purchased the royalty interests on worldwide net sales of ADYNOVATE and MOVANTIK from Nektar Therapeutics. Nektar monetized these non-strategic royalty interests in order to further fund development of its strategic pipeline.
Note: This transaction also appears in the Royalty Monetization section under ADYNOVATE and MOVANTIK.